Nov 2026· Blood Research· Vol 61· 0 citations· 51 references
Medicine
TL;DR
This review has synthesized the latest clinical evidence and international guidelines to provide an updated, evidence-based algorithm for the diagnosis and management of CLL and examined the clinical efficacy reported in pivotal trials involving patients with relapsed/refractory CLL.
Abstract
Chronic lymphocytic leukemia (CLL) management has evolved into a precision-medicine paradigm, with genetic risk factors such as TP53 and IGHV status serving as key determinants of frontline treatment selection. The therapeutic landscape has expanded to include fixed-duration options alongside established continuous regimens. This expansion has enabled personalized management strategies incorporating measurable residual disease-guided treatment approaches aimed at achieving deeper responses while minimizing long-term toxicity and resistance. In a relapsed/refractory setting, treatment selection must be guided by prior treatment exposure, identified molecular mechanisms of resistance, and the availability of novel agents. In this review, we have synthesized the latest clinical evidence and international guidelines to provide an updated, evidence-based algorithm for the diagnosis and management of CLL. Furthermore, we examined the clinical efficacy reported in pivotal trials involving patients with relapsed/refractory CLL and discuss the potential of next-generation therapies, including non-covalent Bruton tyrosine kinase (BTK) inhibitors, BTK degraders, and cellular immunotherapies, to expand treatment options for high-risk patients. Finally, we addressed the clinical challenges of Richter’s transformation, emphasizing the importance of clonality assessment and the urgent need for further clinical trials and innovative therapeutic approaches to improve long-term outcomes in this patient population.
The role of intensive cytarabine plus anthracycline plus anthracycline-based regimens and venetoclax-based lower-intensity approaches are discussed, as well as targeted therapies directed against FLT3, IDH1/2, NPM1, and KMT2A-rearranged AML.
Jennifer Marvin-Peek, F. Ravandi· Journal of Hematology & Onco...· 0 citations
Multiple myeloma (MM) is a malignant plasma cell disorder whose prognosis has significantly improved with the introduction of proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal antibodies, and more recently BCMA-targeted immunotherapies. In 2026, MM is considered a chronic disease requiring individuali...
P. Debureaux, T. Cazaubiel, T. Chalopin et al.· Bulletin du Cancer· 0 citations
It is proposed that the future of DLBCL management lies not merely in the availability of novel agents, but in the rational sequencing and combination of these modalities based on dynamic molecular monitoring and individualized risk assessment—translating molecular insights into actionable clinical pathways.
B. Guo, Hai-Ke Lei, Yao Liu· World Journal of Clinical On...· 0 citations
Allogeneic HSCT remains a major potentially curative treatment for patients with AML at high risk of relapse. However, the rapid development of targeted agents and novel non-intensive therapies has substantially changed the therapeutic landscape, raising questions regarding the optimal timing and indications for transp...
Simona Sica, F. Frioni, M. Breccia et al.· Mediterranean Journal of Hem...· 0 citations